|
GB9304919D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
|
AU684887B2
(en)
*
|
1994-03-09 |
1998-01-08 |
Pfizer Inc. |
Isoxazoline compounds as inhibitors of TNF release
|
|
US5786354A
(en)
*
|
1994-06-21 |
1998-07-28 |
Celltech Therapeutics, Limited |
Tri-substituted phenyl derivatives and processes for their preparation
|
|
US6245774B1
(en)
*
|
1994-06-21 |
2001-06-12 |
Celltech Therapeutics Limited |
Tri-substituted phenyl or pyridine derivatives
|
|
GB9412571D0
(en)
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
|
GB9412573D0
(en)
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
CA2258728C
(en)
|
1996-06-19 |
2011-09-27 |
Rhone Poulenc Rorer Limited |
Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
|
|
GB9622363D0
(en)
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
AU5330698A
(en)
|
1996-12-23 |
1998-07-17 |
Celltech Therapeutics Limited |
Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
|
|
GB9705361D0
(en)
|
1997-03-14 |
1997-04-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US6022977A
(en)
*
|
1997-03-26 |
2000-02-08 |
Dupont Pharmaceuticals Company |
Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
|
|
GB9713087D0
(en)
*
|
1997-06-20 |
1997-08-27 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
DZ3019A1
(fr)
*
|
1999-03-01 |
2005-05-20 |
Smithkline Beecham Corp |
Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
|
|
GB9914258D0
(en)
*
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
PL200923B1
(pl)
|
1999-08-21 |
2009-02-27 |
Nycomed Gmbh |
Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
|
|
JP4195561B2
(ja)
*
|
1999-09-17 |
2008-12-10 |
エルジー ケム インヴェストメント リミティッド |
カスパーゼインヒビター
|
|
KR100399361B1
(ko)
|
1999-11-04 |
2003-09-26 |
주식회사 엘지생명과학 |
캐스파제 억제제 함유 치료제 조성물
|
|
GB9924862D0
(en)
|
1999-10-20 |
1999-12-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
DE19953024A1
(de)
|
1999-11-04 |
2001-05-10 |
Merck Patent Gmbh |
Isoxazolderivate als Phosphodiesterase VII-Hemmer
|
|
GB2362101A
(en)
*
|
2000-05-12 |
2001-11-14 |
Astrazeneca Ab |
Treatment of chronic obstructive pulmonary disease
|
|
WO2002094321A1
(en)
|
2001-05-23 |
2002-11-28 |
Tanabe Seiyaku Co., Ltd. |
Compositions for promoting healing of bone fracture
|
|
KR20040007583A
(ko)
|
2001-05-23 |
2004-01-24 |
다나베 세이야꾸 가부시키가이샤 |
연골 질환의 재생치료용 조성물
|
|
IL159120A0
(en)
*
|
2001-05-29 |
2004-05-12 |
Schering Ag |
Cdk inhibiting pyrimidines, production thereof and their use as medicaments
|
|
WO2002100332A2
(en)
|
2001-06-08 |
2002-12-19 |
Cytokine Pharmasciences, Inc. |
Isoxazoline compounds having mif antagonist activity
|
|
CA2450073C
(en)
|
2001-07-25 |
2017-08-29 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for modulating blood-brain barrier transport
|
|
AR039385A1
(es)
*
|
2002-04-19 |
2005-02-16 |
Astrazeneca Ab |
Derivados de tioxantina como inhibidores de la mieloperoxidasa
|
|
AU2003301903A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Bristol-Myers Squibb Company |
Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
JP2006522151A
(ja)
|
2003-04-01 |
2006-09-28 |
アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ |
不妊症におけるホスホジエステラーゼ阻害剤
|
|
KR100594544B1
(ko)
*
|
2003-08-27 |
2006-06-30 |
주식회사 엘지생명과학 |
이소옥사졸린 구조를 갖는 캐스파제 저해제
|
|
RU2387646C2
(ru)
*
|
2003-08-29 |
2010-04-27 |
Рэнбакси Лабораториз Лимитед |
Ингибиторы фосфодиэстеразы типа-iv
|
|
SE0302756D0
(sv)
*
|
2003-10-17 |
2003-10-17 |
Astrazeneca Ab |
Novel Compounds
|
|
US20070259874A1
(en)
*
|
2003-11-26 |
2007-11-08 |
Palle Venkata P |
Phosphodiesterase Inhibitors
|
|
BRPI0508140B1
(pt)
|
2004-03-05 |
2015-03-17 |
Nissan Chemical Ind Ltd |
Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo"
|
|
BRPI0507818A
(pt)
*
|
2004-03-26 |
2007-07-10 |
Cytokine Pharmasciences Inc |
composto e métodos de inibição
|
|
US20080009535A1
(en)
*
|
2004-08-30 |
2008-01-10 |
Sarala Balachandran |
Inhibitors of phosphodiesterase type-IV
|
|
SE0402591D0
(sv)
*
|
2004-10-25 |
2004-10-25 |
Astrazeneca Ab |
Novel use
|
|
MY140748A
(en)
|
2004-12-06 |
2010-01-15 |
Astrazeneca Ab |
Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
|
|
ES2370788T3
(es)
*
|
2005-02-07 |
2011-12-22 |
Aerocrine Ab |
Controlar flujo de aliento exhalado durante análisis.
|
|
WO2006097273A1
(en)
*
|
2005-03-15 |
2006-09-21 |
Ganial Immunotherapeutics Inc. |
Compounds having immunomodulator activity
|
|
EP2671508B1
(de)
|
2005-04-28 |
2020-09-16 |
Proteus Digital Health, Inc. |
Pharma-Informatiksystem
|
|
ES2351161T3
(es)
*
|
2005-05-03 |
2011-02-01 |
Ranbaxy Laboratories Limited |
Inhibidores de la fosfodiesterasa a base de azol.
|
|
EP2275096A3
(de)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenese durch modulation des Muscarinrezeptors
|
|
EP2258357A3
(de)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenese mit Acetylcholinesterasehemmer
|
|
WO2007047978A2
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
EP2314289A1
(de)
|
2005-10-31 |
2011-04-27 |
Braincells, Inc. |
Gaba-rezeptor-vermittelte modulation von neurogenese
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
CA2643199A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
|
EP2021000A2
(de)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenese mittels angiotensin-modulation
|
|
TW200804383A
(en)
*
|
2006-06-05 |
2008-01-16 |
Astrazeneca Ab |
New compounds
|
|
WO2008030651A1
(en)
*
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
JP2010503710A
(ja)
|
2006-09-18 |
2010-02-04 |
ラプトール ファーマシューティカル インコーポレイテッド |
受容体関連タンパク質(rap)結合体の投与による肝障害の処置
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP2066355A2
(de)
*
|
2006-09-19 |
2009-06-10 |
Braincells, Inc. |
Kombination aus einem durch einen peroxisom-proliferator aktivierten rezeptor-mittel und einem zweiten neurogenen mittel zur behandlung von erkrankungen des nervensystems sowie zur förderung von neuraler differenzierung und neurogenese
|
|
WO2008035316A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
ES2627848T3
(es)
|
2008-06-04 |
2017-07-31 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
ES2919563T3
(es)
|
2009-02-20 |
2022-07-27 |
Enhanx Biopharm Inc |
Sistema de administración de medicamentos a base de glutatión
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
KR20180114970A
(ko)
|
2009-05-06 |
2018-10-19 |
라보라토리 스킨 케어, 인크. |
활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
|
MX357121B
(es)
|
2011-03-01 |
2018-06-27 |
Synergy Pharmaceuticals Inc Star |
Proceso de preparacion de agonistas c de guanilato ciclasa.
|
|
DK2691379T3
(en)
|
2011-03-31 |
2017-02-13 |
Bayer Ip Gmbh |
HERBICID AND FUNGICID ACTIVE 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES AND 3-PHENYLISOXAZOLIN-5-THIOAMIDES
|
|
WO2013106547A1
(en)
|
2012-01-10 |
2013-07-18 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
US20150064221A1
(en)
|
2012-04-17 |
2015-03-05 |
Niranjan Y. Sardesai |
Compounds having immunomudulator activity
|
|
BR112015006573B1
(pt)
*
|
2012-09-25 |
2020-11-03 |
Bayer Cropscience Ag |
derivados de 3-fenilisoxazolina, compoisições herbicidas, seus usos, e método para controle de plantas indesejáveis
|
|
ES2636596T3
(es)
*
|
2012-11-20 |
2017-10-06 |
Biogen Ma Inc. |
Agentes moduladores de S1P y/o ATX
|
|
EP2958577A2
(de)
|
2013-02-25 |
2015-12-30 |
Synergy Pharmaceuticals Inc. |
Guanylat-cyclase-rezeptoragonisten zur verwendung bei der darmreinigung
|
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
|
EP2968439A2
(de)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Zusammensetzungen zur behandlung von magen-darm-störungen
|
|
PL3004138T3
(pl)
|
2013-06-05 |
2024-07-29 |
Bausch Health Ireland Limited |
Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
|
|
CN103381157A
(zh)
*
|
2013-07-04 |
2013-11-06 |
丁圣雨 |
Chukrasone B在治疗慢性阻塞性肺疾病的药物中的应用
|
|
CA2920856C
(en)
|
2013-08-09 |
2026-03-03 |
Ardelyx, Inc. |
Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
|
|
CN106573924B
(zh)
*
|
2014-04-22 |
2019-06-25 |
诺华股份有限公司 |
作为LpxC抑制剂的异噁唑啉异羟肟酸衍生物
|
|
EA202090018A1
(ru)
|
2017-06-13 |
2020-05-26 |
Байер Акциенгезельшафт |
Гербицидно-активные 3-фенилизоксазолин-5-карбоксамиды тетрагидро- и дигидрофурановых карбоксамидов
|
|
SI3638665T1
(sl)
|
2017-06-13 |
2021-11-30 |
Bayer Aktiengesellschaft |
Herbicidni 3-fenilizoksazolin-5-karboksamidi tetrahidro in dihidrofuran karboksilnih kislin in estrov
|
|
EP3668845B1
(de)
|
2017-08-17 |
2024-06-26 |
Bayer Aktiengesellschaft |
Herbizid wirksame 3-phenyl-5-trifluormethylisoxazolin-5-carboxamide von cyclopentylcarbonsäuren und -estern
|
|
EP3743411B1
(de)
|
2018-01-25 |
2022-12-21 |
Bayer Aktiengesellschaft |
Herbizid wirksame 3-phenylisoxazolin-5-carboxamide von cyclopentenylcarbonsäurederivaten
|
|
CA3133025A1
(en)
|
2019-03-12 |
2020-09-17 |
Bayer Aktiengesellschaft |
Herbicidally active 3-phenylisoxazoline-5-carboxamides of s-containing cyclopentenyl carboxylic acid esters
|
|
JP2022533251A
(ja)
|
2019-05-21 |
2022-07-21 |
アルデリックス, インコーポレイテッド |
患者において血清リン酸塩を低下させるための組み合わせ
|